1 Min Read
Jan 23 (Reuters) - Resverlogix Corp
* Announced preliminary results from New Zealand based Phase 1 trial with severe kidney (renal) impaired patients Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.